Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland.
Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland.
Testing for Mepolizumab Biosimilar Begins
Bio-Thera Solutions began a phase 1 study for a biosimilar candidate referencing Nucala (mepolizumab). The study would assess the pharmacokinetics and safety of the biosimilar (BAT2606) in healthy participants.
The randomized, double-blind, parallel group, single-dose study will include 207 healthy volunteers. Mepolizumab is an interleukin 5 antagonist monoclonal antibody that can be administered subcutaneously with a syringe or autoinjector device. Nucala is used to treat:
After the study is completed, Bio-Thera will conduct a global phase 3 study. The company said that it plans to apply for regulatory approval in the United States, China, the European Union, and other markets around the world.
Biocon Biologics Licenses Out to Yoshindo
Biocon Biologics entered into a licensing agreement with Yoshindo for the Japanese commercialization of 2 biosimilar candidates: an ustekinumab biosimilar and a denosumab biosimilar.
Under the deal’s terms, Yoshindo would have exclusive commercialization rights for the biosimilars in Japan in exchange for $700 million. Biocon Biologics would receive an upfront license fee along with additional payments dependent on the achievement of development milestones over the next few years. The companies did not disclose the exact financial terms of the deal.
The ustekinumab biosimilar references Stelara and will be used to treat autoimmune conditions including, psoriasis, Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The denosumab candidate references Prolia and is used to treat patients with osteoporosis and patients undergoing cancer treatments who are at a high risk of fracture. Phase 1 and phase 3 clinical trials for the biosimilars began in 2022.
“Once approved, these products will expand our offering of affordable, high quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas,” said Shreehas Tambe, deputy CEO of Biocon Biologics, in a statement.
Hukyndra Launches in Switzerland
Alvotech and STADA Arzneimittel announced that they launched Hukyndra, an adalimumab biosimilar referencing Humira, in Switzerland. Hukyndra launched as a high-concentration, low-volume, citrate-free formulation.
“Significant unmet needs for access to biologics exist for patients across Europe…. Our partnership with Alvotech enables STADA to deliver a broad range of high-quality biosimilars to European patients. Launches of Hukyndra in multiple markets is evidence of our commitment to broader access to critical therapies,” said Bryan Kim, head of global specialty and executive vice president of STADA.
STADA and Alvotech entered into their partnership in November 2019. The agreement includes 7 biosimilars, including Hukyndra. Alvotech is responsible for development and manufacturing and STADA is in charge of commercialization. In Switzerland, Hukyndra is being marketed by Spirig HealthCare, a subsidiary of STADA. The biosimilar will be made available in 80 mg/0.8mL and 40 mg/0.4 mL syringes for self-administration and 40 mg/0.4 mL prefilled autoinjector pens.
The European Medicines Agency granted Hukyndra marketing authorization in November 2021. In addition to Switzerland, Hukyndra is available in Austria, Estonia, France, Finland, Germany, Lithuania, Slovakia, and Sweden. The biosimilar has also been approved in the United Kingdom and is under review in the United States.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.